Table 2.
Baseline sociodemographic and clinical characteristics of patients receiving tamoxifen followed by exemestane (sequential group), patients receiving only exemestane (exemestane group), and the control group
| Characteristic | Sequential group (n = 91) | Exemestane group (n = 113) | Control group (n = 123) | P |
|---|---|---|---|---|
| Age at random assignment, Mean (SD), y | 69.6 (7.9) | 69.2 (7.0) | 66.9 (8.0) | .02a |
| IQ, Mean (SD) | 100.1 (19.9) | 99.4 (18.8) | 105.3 (19.0) | .04b |
| Time since surgery, Mean (SD), mo | 1.3 (0.7) | 1.5 (0.7) | .13 | |
| Age at menopause, Mean (SD), y | 49.3 (5.3) | 49.7 (4.5) | 48.2 (6.1) | .07 |
| Radiotherapy at baseline or later, No. (%) | 49 (57) | 75 (68) | .17 | |
| Ever use of HRT, No. (%) | 14 (15) | 20 (18) | 23 (19) | .10 |
a
Post hoc test: sequential group vs control group: P = .01; exemestane group vs control group: P = .02; sequential group vs exemestane group: P = .68. HRT = hormone replacement therapy; IQ = intelligence quotient.
b
Post hoc test: sequential group vs control group: P = .05; exemestane group vs control group: P = .02; sequential group vs exemestane group: P = .79.